Global Combined Pituitary Hormone Deficiencies Market
市场规模(十亿美元)
CAGR : %
Forecast Period |
2023 –2030 |
Market Size (Base Year) |
USD 1.86 Billion |
Market Size (Forecast Year) |
USD 2.71 Billion |
CAGR |
|
Major Markets Players |
|
全球联合性垂体激素缺乏症市场,按治疗(激素替代疗法、药物治疗等)、诊断(血液检查、影像学检查等)、遗传(常染色体显性遗传、常染色体隐性和 X 连锁隐性遗传)、最终用户(医院、专科诊所、家庭护理等)、分销渠道(医院药房、零售药房、网上药房等)划分 - 行业趋势和预测到 2030 年。
联合垂体激素缺乏症市场分析和规模
在过去的二十年中,人们对垂体发育机制的理解有了很大的提高。自首次报道 POU1F1 人类突变导致明确表型而无垂体外畸形以来,已记录了具有不同程度表型-基因型相关性的不同转录因子遗传异常。尽管发现越来越多的孤立性或多重垂体功能障碍的遗传原因,但大多数先天性垂体功能低下症患者(80-90%)的病因仍然未知。确定新的病因至关重要,既可以作为产后诊断以更好地识别和治疗患者(延迟性垂体功能障碍、MRI上的垂体肿瘤鉴别诊断等),也可以作为产前诊断以降低过早死亡的风险。
Data Bridge Market Research 分析称,2022 年联合垂体激素缺乏症市场规模为 18.59 亿美元,到 2030 年将飙升至 27.12 亿美元,预计在预测期内的复合年增长率为 4.70%。由于通过血液检测诊断激素相关疾病的需求不断增长,“血液检测”在联合垂体激素缺乏症市场的诊断部分占据主导地位。除了对市场价值、增长率、细分、地理覆盖范围和主要参与者等市场情景的洞察外,Data Bridge Market Research 整理的市场报告还包括深度专家分析、患者流行病学、渠道分析、定价分析和监管框架。
联合垂体激素缺乏症市场范围和细分
报告指标 |
细节 |
预测期 |
2023 至 2030 年 |
基准年 |
2022 |
历史岁月 |
2021 (可定制为 2015-2020) |
定量单位 |
收入(百万美元)、销量(单位)、定价(美元) |
涵盖的领域 |
按治疗(激素替代疗法、药物治疗等)、诊断(血液检查、影像学检查等)、遗传(常染色体显性遗传、常染色体隐性遗传和 X 连锁隐性遗传)、最终用户(医院、专科诊所、家庭护理等)、分销渠道(医院药房、零售药房、网上药房等) |
覆盖国家 |
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America |
Market Players Covered |
Pfizer Inc. (U.S.), GlaxoSmithKline plc (U.K.), Novartis AG (Switzerland), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd.(Israel), Sanofi (France), F. Hoffmann-La Roche Ltd. (Switzerland), Zydus Cadila (India), Lupin (India), Amneal Pharmaceuticals LLC. (U.S.), Cipla Inc. (U.S.), Aurobindo Pharma (India), Glenmark Pharmaceuticals Limited (India), Eli Lilly and Company (U.S.), Sun Pharmaceutical Industries Ltd. (India), Allergan (Ireland), Bristol-Myers Squibb Company (U.S.), Takeda Pharmaceutical Company Limited (Japan), Abbott (U.S.). LEO Pharma A/S (Denmark) |
Market Opportunities |
|
Market Definition
The pituitary gland regulates growth, fertility, stress response, and metabolism in humans. The pituitary gland's development is guided by a complex algorithm of interacting transcription factors and signaling molecules. Mutations cause pituitary insufficiency in any of the genes involved in pituitary development, leading to decreased or absent pituitary hormone output. Combined pituitary hormone deficiencies (CPHD) is defined as GH insufficiency combined with a deficiency in one or more other anterior pituitary-derived hormones. The cause of CPHD is unknown, partly because of wide regional disparities in incidence; nonetheless, genetic factors are relatively uncommon. A proper hormone replacement is essential. As individuals develop new impairments, constant follow-up is required (for instance late onset corticotroph deficiency in patients with PROP1 mutations).
Global Combined Pituitary Hormone Deficiencies Market Dynamics
Drivers
- Increasing prevalence of combined pituitary hormone deficiencies
The rising prevalence of combined pituitary hormone deficiencies is estimated to enhance the market's growth rate. A deficiency of numerous hormones produced by the pituitary gland, which is located at the base of the brain, is known as combined pituitary hormone deficiency. A deficiency of these hormones may have an impact on the development of various body components. Failure to grow at the predicted rate and low stature are the initial indicators of this disorder, which usually appear in early childhood.
- Increasing investment in healthcare infrastructure
Another significant factor influencing the growth rate of the combined pituitary hormone deficiencies market is the rising healthcare expenditure which helps in improving its infrastructure. Also, various government organizations aim to improve the healthcare infrastructure by increasing funding and this will further influence the market dynamics.
- Surging incidences of hypothyroidism
The rising incidences of hypothyroidism is anticipated to enhance the market’s growth rate. Hypothyroidism, or under activity of the butterfly-shaped thyroid gland in the lower neck, can occur in people with combined pituitary hormone insufficiency. Weight gain and weariness are two common signs of hypothyroidism. Delay or absence of puberty and the inability to conceive biological offspring are further symptoms of combined pituitary hormone insufficiency.
- Growing investment in healthcare facilities
Surging focus towards improving the condition of healthcare facilities and improving the overall healthcare infrastructure another important factor fostering the growth of the market. Rising number of partnerships and strategic collaborations between the public and private players pertaining to funding and application of new and improved technology is further creating lucrative market opportunities.
Opportunities
- Technological advancements for combined pituitary hormone deficiencies
The market for combined pituitary hormone deficiencies presents opportunities for technological advancements in diagnostics, drug delivery systems, and treatment modalities. Innovations in diagnostic techniques, such as imaging modalities and hormone assays, can help in early detection and accurate diagnosis of the condition. Additionally, the development of novel drug delivery systems, such as long-acting formulations and implants, can enhance patient compliance and convenience. Advancements in treatment modalities, including gene therapy and targeted therapies, hold promise for more effective and personalized treatment options.
- Increasing focus on patient-centric approach
There is an increasing focus on patient-centric approaches in healthcare, and this presents opportunities for the combined pituitary hormone deficiencies market. Personalized medicine, which involves tailoring treatment plans based on individual patient characteristics, is gaining traction. By adopting a patient-centric approach, pharmaceutical companies can develop targeted therapies that address specific hormone deficiencies and minimize side effects. Furthermore, patient education and awareness programs can empower individuals to seek timely diagnosis and treatment, driving market growth.
Restraints
- High cost of treatment
The high cost associated with the diagnosis, treatment, and long-term management of combined pituitary hormone deficiencies can be a significant restraint for the market. Hormone replacement therapy, surgeries, and diagnostic tests can be expensive, especially for patients without adequate insurance coverage or in regions with limited access to healthcare services. The cost burden can deter patients from seeking proper diagnosis and treatment, thereby limiting market growth.
- Limited awareness and underdiagnosis
Combined pituitary hormone deficiencies often go undiagnosed or misdiagnosed due to the non-specific nature of the symptoms and the lack of awareness among both patients and healthcare providers. This results in delayed or inadequate treatment, negatively impacting patient outcomes. Limited awareness also hinders market growth by reducing the demand for diagnostic tests and treatment options.
Challenges
- Complex diagnosis and treatment
Combined pituitary hormone deficiencies involve multiple hormones and can present with a wide range of symptoms, making diagnosis challenging. Differentiating between primary and secondary hormone deficiencies requires thorough evaluation and specialized testing. Additionally, the treatment approach often involves the use of multiple hormone replacement therapies and requires long-term management, which can be complex and require close monitoring. The complexity of diagnosis and treatment poses challenges for healthcare providers in accurately identifying and effectively managing the condition.
- Limited treatment options
Despite advancements in the field, the available treatment options for combined pituitary hormone deficiencies remain limited. Hormone replacement therapy is the mainstay of treatment, but it may not fully restore normal hormonal balance, and some patients may experience suboptimal response or side effects. Surgical interventions and radiation therapy are reserved for specific cases, and their efficacy may vary. The lack of diverse and highly effective treatment modalities restricts the ability to tailor therapy to individual patients and achieve optimal outcomes.
This combined pituitary hormone deficiencies market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the combined pituitary hormone deficiencies market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Recent Development
- In June 2022, Halozyme Therapeutics, Inc. announced the commercial launch of TLANDO (testosterone undecanoate), an oral treatment indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone
- In February 2022, Pfizer Inc. and OPKO Health, Inc. announced that the European Commission has granted marketing authorization for the next-generation long-acting recombinant human growth hormone NGENLA, a once-weekly injection to treat children and adolescents from 3 years of age with growth disturbance due to insufficient secretion of growth hormone.
Global Combined Pituitary Hormone Deficiencies Market Scope
The global combined pituitary hormone deficiencies market is segmented on the basis of inheritance, treatment, diagnosis, end-users, and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Inheritance
- Autosomal Dominant
- Autosomal Recessive
- X-linked Recessive
Treatment
- Hormone Replacement Therapy Medication
- Levothyroxine
- Corticosteroids
- Others
Diagnosis
- Blood Tests
- Imaging Tests
- Others
- Others
End-Users
- Hospitals
- Specialty Clinics
- Homecare
- Others
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Others
Combined Pituitary Hormone Deficiencies Market Regional Analysis/Insights
The combined pituitary hormone deficiencies market is analysed and market size insights and trends are provided by country, inheritance, treatment, diagnosis, end-users, and distribution channel as referenced above.
The countries covered in the combined pituitary hormone deficiencies market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America is expected to dominate the combined pituitary hormone deficiencies market because of the well-established healthcare infrastructure and rising awareness among the population in this region. Additionally, the growing presence of major key players will further propel the market’s growth rate in this region.
Asia-Pacific is expected to grow during the forecast period due to the increasing penetration of novel drugs and rising healthcare expenditure in this region. Also, growing government initiatives will further cushion the market’s growth rate in this region.
报告的国家部分还提供了影响单个市场因素和国内市场监管变化,这些因素和变化会影响市场的当前和未来趋势。下游和上游价值链分析、技术趋势和波特五力分析、案例研究等数据点是用于预测单个国家市场情景的一些指标。此外,在提供国家数据的预测分析时,还考虑了全球品牌的存在和可用性以及它们因来自本地和国内品牌的激烈或稀缺竞争而面临的挑战、国内关税和贸易路线的影响。
医疗保健基础设施增长安装基础和新技术渗透
联合垂体激素缺乏症市场还为您提供每个国家/地区资本设备医疗保健支出增长、联合垂体激素缺乏症市场不同类型产品的安装基数、使用生命线曲线的技术的影响以及医疗保健监管情景的变化及其对联合垂体激素缺乏症市场的影响的详细市场分析。数据适用于 2025-2020 年的历史时期。
竞争格局和联合垂体激素缺乏症市场份额分析
全球联合垂体激素缺乏症市场竞争格局提供了按竞争对手划分的详细信息。详细信息包括公司概况、公司财务状况、收入、市场潜力、研发投资、新市场计划、全球影响力、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度、应用主导地位。以上提供的数据点仅与公司对联合垂体激素缺乏症市场的关注有关。
全球联合垂体激素缺乏症市场的一些主要参与者包括:
- 辉瑞公司(美国)
- 葛兰素史克公司 (英国)
- 诺华公司(瑞士)
- Mylan NV(美国)
- Teva Pharmaceutical Industries Ltd.(以色列)
- 赛诺菲(法国)
- F. Hoffmann-La Roche Ltd.(瑞士)
- Zydus Cadila(印度)
- 鲁冰花(印度)
- Amneal Pharmaceuticals LLC.(美国)
- Cipla Inc.(美国)
- Aurobindo Pharma(印度)
- Glenmark 制药有限公司(印度)
- 礼来公司 (美国)
- 太阳制药工业有限公司 (印度)
- 艾尔建(爱尔兰)
- 百时美施贵宝公司 (美国)
- 武田药品工业株式会社 (日本)
- 雅培(美国)
- LEO Pharma A/S(丹麦)
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
研究方法
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
可定制
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.